Myocardial infarction associated with intravenous immune globulin

Annals of Pharmacotherapy

Volumn 39, Issue 12, 2005, Pages 2114-2118

  Stenton, Sunita Bond ^a,b   Dalen, Dawn ^b,c   Wilbur, Kerry ^b,d  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Interior Health Authority   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Intravenous immune globulin; Myocardial infarction

Indexed keywords

ALLOPURINOL; IMMUNOGLOBULIN; TROPONIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CASE REPORT; DISEASE ASSOCIATION; EXERCISE TEST; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; NARANJO PROBABILITY SCALE; PRIORITY JOURNAL; RATING SCALE; THORAX PAIN; TOXIC EPIDERMAL NECROLYSIS; VIET NAM;

AGED; AGED, 80 AND OVER; ALLOPURINOL; CHEST PAIN; EPIDERMAL NECROLYSIS, TOXIC; GOUT SUPPRESSANTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 28544452976     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G104     Document Type: Article

References (24)

1. Dalakas M. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 2004;291:2367-75.
2. Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease. Am J Clin Dermatol 2004;5:153-60.
3. Viard I, Wherli P, Bullani R, Schneider P, Huller N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD35 with human intravenous immunoglobulin. Science 1998;282:490-3.
4. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;97(suppl 1):79-83.
5. Naranjo C, Busto U, Sellers E, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
6. Woodruff R, Grigg A, Firkin F, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;2:217-8.
7. Reinhart W, Berchtold P. Effect of high dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-4.
8. Ropper A, Adelman L. Early Guillain-Barré syndrome without inflammation. Arch Neurol 1992;49:979-81.
9. Fisman D, Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 1997;13:775-7.
10. Rosenbaum J. Myocardial infarction as a complication of immunoglobulin therapy. Arthritis Rheum 1997;40:1732-3.
11. Elkayam O, Paran D, Milo R. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders. A study of four cases. Ann Rheum Dis 2000;59:77-80.
12. Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (TTP). Am J Hematol 2000;65:177-8.
13. Struble E, Dice Y. Intravenous immune globulin (IVIG) precipitating acute myocardial infarction. J Miss State Med Assoc 2002;43:115.
14. Crouch E, Watson L. Intravenous immunoglobulin-related acute coronary syndrome and coronary angiography in idiopathic thrombocytopenic purpura-a case report and literature review. Angiology 2002;53:113-7.
15. Zaidan R, Al Moallem M, Wani B. Thrombosis complicating high dose intravenous immunoglobulin: a report of three cases and a review of the literature. Eur J Neurol 2003;10:367-72.
16. Stamboulis E, Theodorou V, Kilidireas K, Apostolou T. Acute myocardial infarction following intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy in association with a monoclonal immunoglobulin G paraprotein. Eur Neurol 2004;51:51.
17. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2004;83:661-5.
18. Canadian Adverse Drug Reaction Monitoring Program. Summary of reported adverse drug reactions: immunoglobulin (human) from 1997 to 2004. www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/adr_guideline_e.html (accessed 2004 Oct 17).
19. Turner B, Wills A. Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 2000;68:790-1.
20. Go R, Call T. Deep vein thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000;75:83-5.
21. Oh K, Boldt H, Danis R. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997;124:416-8.
22. Braunwald E, Antmann E, Beasely J, CAliff RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. www.acc.org/clinical/guidelines/unstable/update_index.htm (accessed 2004 Oct 3).
23. Dalakas M. High dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-6.
24. Alliot C, Rapin J, Besson M. Pulmonary embolism after intravenous immunoglobulin. J R Soc Med 2001;94:187-8.